CN114712305B - In-situ dihydromyricetin-loaded BSA gel sterilization material, and preparation method and application thereof - Google Patents
In-situ dihydromyricetin-loaded BSA gel sterilization material, and preparation method and application thereof Download PDFInfo
- Publication number
- CN114712305B CN114712305B CN202210425222.2A CN202210425222A CN114712305B CN 114712305 B CN114712305 B CN 114712305B CN 202210425222 A CN202210425222 A CN 202210425222A CN 114712305 B CN114712305 B CN 114712305B
- Authority
- CN
- China
- Prior art keywords
- dihydromyricetin
- bsa
- gel
- situ
- loaded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 title claims abstract description 202
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 title claims abstract description 101
- 239000000463 material Substances 0.000 title claims abstract description 85
- 230000001954 sterilising effect Effects 0.000 title claims abstract description 70
- 238000004659 sterilization and disinfection Methods 0.000 title claims abstract description 69
- 238000011065 in-situ storage Methods 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 15
- 239000013543 active substance Substances 0.000 claims abstract description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 91
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 35
- 108010024636 Glutathione Proteins 0.000 claims description 16
- 229960003180 glutathione Drugs 0.000 claims description 16
- 230000000844 anti-bacterial effect Effects 0.000 claims description 12
- 238000007254 oxidation reaction Methods 0.000 claims description 10
- 238000006722 reduction reaction Methods 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 230000001590 oxidative effect Effects 0.000 claims description 5
- 241001122767 Theaceae Species 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 14
- 230000007774 longterm Effects 0.000 abstract description 8
- 230000008569 process Effects 0.000 abstract description 4
- 230000002349 favourable effect Effects 0.000 abstract description 3
- 239000000499 gel Substances 0.000 description 88
- 239000000243 solution Substances 0.000 description 18
- 241000894006 Bacteria Species 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000000857 drug effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 241001018563 Nekemias grossedentata Species 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 241000563984 Ampelopsis Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a BSA gel sterilization material loaded with dihydromyricetin in situ, and a preparation method and application thereof. The gel sterilization material is formed by uniformly loading active substances containing dihydromyricetin in a BSA gel material, and the gel sterilization material utilizes gel with a three-dimensional network structure constructed by BSA to load the dihydromyricetin with broad-spectrum sterilization performance in situ, is favorable for the slow release process of the dihydromyricetin, achieves the effects of long-term and continuous sterilization, has better biocompatibility, and can be widely applied to clinical preparations.
Description
Technical Field
The invention relates to a gel sterilization material, in particular to a BSA gel sterilization material loaded with dihydromyricetin in situ, and also relates to a preparation method of the gel sterilization material loaded with dihydromyricetin in situ and application of the gel sterilization material in preparation of sterilization agents, belonging to the technical field of biomedical materials.
Background
Bacterial infection is a major cause of various diseases in the human body, such as intact skin and mucous membrane are natural barriers preventing bacteria from invading the human body, from which bacteria are liable to invade the body after breakage. Dihydromyricetin is extracted from a woody vine plant of Ampelopsis genus of Vitaceae family, such as Ampelopsis grossedentata, has effects of scavenging free radicals, resisting oxidation, resisting thrombi, resisting tumor, diminishing inflammation, etc., especially has broad-spectrum antibacterial and bacteriostatic effects, and is a new generation of natural antibiotics, such as has obvious inhibition effect on common pathogenic bacteria in oral cavity and respiratory tract such as Staphylococcus aureus, staphylococcus epidermidis, beta-hemolytic streptococcus, escherichia coli, proteus vulgaris, pseudomonas aeruginosa, etc. However, dihydromyricetin is poor in water solubility and stability, resulting in limited application in clinical formulation.
Disclosure of Invention
Aiming at the problems of poor water solubility and stability and the like of the dihydromyricetin in the using process, the invention aims to provide the in-situ loaded dihydromyricetin BSA gel sterilization material, the active substances containing the dihydromyricetin are uniformly loaded in the BSA gel material, so that the solubility of the dihydromyricetin is improved, and the dihydromyricetin can be slowly released in the using process of the material because the dihydromyricetin is embedded in the gel material, so that the sterilization effect is realized, the long-term stability and effectiveness of the drug effect are realized, the dihydromyricetin contained in the gel sterilization material is derived from vine tea, the broad-spectrum antibacterial property is realized, the carrier material is derived from bovine serum, the structural similarity with human serum albumin is 76%, the biocompatibility of the gel sterilization material is improved, the BSA gel has better wetting property, and the drug effect of the dihydromyricetin is favorable to be exerted.
The second object of the invention is to provide a preparation method of a BSA gel sterilization material with simple operation, mild condition and low cost and in situ loading of dihydromyricetin, which takes BSA as a raw material, obtains three-dimensional network structure gel through reduction and oxidation reaction, and DMSO is not only used as an oxidant, but also used as a solvent of active substances containing dihydromyricetin, can improve the solubility of the dihydromyricetin, realize uniform dispersion and in situ loading of the dihydromyricetin in the gel, improve the sterilization performance of the gel material, simultaneously has higher glutathione content in human body as a reducing agent, has low DMSO biotoxicity as an oxidant and a solvent, can further improve the biocompatibility of the gel sterilization material, has simple operation, mild condition and low cost in the preparation process of the whole sterilization material, and is excellent in the performance of the obtained sterilization material, favorable for industrial production and has obvious advantages compared with the prior art.
The third purpose of the invention is to provide the application of the in-situ loading dihydromyricetin BSA gel sterilization material, and the application of the in-situ loading dihydromyricetin BSA gel sterilization material in preparation of a medicament with sterilization effect, wherein the obtained sterilization medicament can slowly release the active ingredient of the dihydromyricetin sterilization, has long-term stable and effective drug effect, and has better inactivation effect on common bacteria such as escherichia coli, staphylococcus aureus and the like.
In order to achieve the technical aim, the invention provides a BSA gel sterilization material loaded with dihydromyricetin in situ, which is formed by uniformly loading active substances containing dihydromyricetin into the BSA gel material.
The in-situ dihydromyricetin-loaded BSA gel sterilization material disclosed by the invention contains the dihydromyricetin active ingredient which is derived from vine tea, has broad-spectrum antibacterial property, and BSA is derived from bovine serum, and BSA and human serum albumin have 76% of similarity in structure, so that the gel sterilization material prepared by compounding the BSA and the human serum albumin has good biocompatibility, meanwhile, the solubility of the dihydromyricetin is improved, and the BSA gel has good wettability, so that the efficacy of the dihydromyricetin is exerted. Because the dihydromyricetin is embedded in the gel, the dihydromyricetin can be slowly released in the use process of the material, the sterilization effect is achieved, and the long-term stability and effectiveness of the drug effect are realized. Therefore, the dihydromyricetin is loaded in the BSA gel material, and the dihydromyricetin and the BSA gel material form obvious synergistic effect, so that on one hand, the solubility of the dihydromyricetin can be improved, the biocompatibility of the whole material is promoted, and on the other hand, the dihydromyricetin can be slowly released, and the long-term stable sterilization effect is realized.
As a preferred scheme, the BSA gel material is obtained by sequentially subjecting BSA to glutathione reduction and DMSO oxidation.
The BSA gel material adopts BSA, glutathione and biological low-toxicity DMSO as reaction raw materials, has good biocompatibility, can generate synergistic effect with dihydromyricetin, is beneficial to the exertion of the drug effect of the dihydromyricetin, realizes the slow release of the dihydromyricetin, and achieves the long-term stable sterilization effect.
As a preferred scheme, the active substance containing dihydromyricetin is dihydromyricetin and/or vine tea extract containing dihydromyricetin.
The BSA gel material can effectively load dihydromyricetin and ampelopsis grossedentata extract containing dihydromyricetin, and the dihydromyricetin and the ampelopsis grossedentata extract containing dihydromyricetin can be compounded with the BSA gel material to form the gel sterilization material with excellent performance.
As a preferable scheme, the content of dihydromyricetin in the active substance containing dihydromyricetin in the BSA gel material is 3-5 mg/mL.
The content of dihydromyricetin in the BSA gel material has a great influence on the material performance, and needs to be controlled within a certain range. If the content of dihydromyricetin in the BSA gel material is too low, the gel material cannot play an effective bactericidal role; if the dihydromyricetin content is too high, the gel material is liable to have a certain cytotoxicity.
The invention also provides a preparation method of the in-situ loading dihydromyricetin BSA gel sterilization material, which comprises the steps of adding glutathione into BSA solution to perform reduction reaction, and then adding DMSO solution containing active substances containing dihydromyricetin to perform oxidation reaction.
The invention adopts BSA as a carrier material, BSA molecules contain rich disulfide bonds, glutathione can reduce the disulfide bonds in the BSA to form free sulfhydryl groups, and DMSO has weak oxidizing property, and can oxidize the free sulfhydryl groups to regenerate disulfide bonds to form a three-dimensional network structure, so that the gel is prepared. In addition, compared with water, the solubility of the dihydromyricetin in DMSO is greatly improved, and the active substance containing the dihydromyricetin is dissolved in DMSO in advance, so that the dihydromyricetin can be embedded in gel while the DMSO reacts with BSA.
As a preferable scheme, the temperature of the reduction reaction is 40-50 ℃ and the reaction time is 3-6 h.
As a preferable scheme, the temperature of the oxidation reaction is 40-50 ℃ and the reaction time is 1-3 h.
Because BSA used in the invention belongs to protein substances, the BSA has certain requirements on temperature, and when the reaction temperature exceeds 60 ℃, protein denaturation is easy to cause, and starch protein fibers are formed; gel formation is not favored when the temperature is too low, whereas gel formation is favored at slightly higher temperatures of 40-50 c.
As a preferable scheme, the BSA solution has a mass percentage concentration of 30% -50%.
As a preferred embodiment, the glutathione is added to the BSA solution at a concentration of 30 to 50mM.
In the invention, BSA is a gel main body material, the gel formation is affected by too low concentration of BSA, and the gel is hardened by too high concentration. Glutathione is used as a reducing agent to reduce disulfide bonds of BSA into free sulfhydryl groups, if the concentration of glutathione is too low, BSA cannot be reduced sufficiently, but too high concentration of glutathione can lead to gel with certain cytotoxicity.
As a preferred embodiment, the volume ratio of DMSO to BSA solution is 1: 15-25. The concentration of dihydromyricetin in the DMSO is 80-100 mg/mL.
DMSO in the present invention has two effects, one is to oxidize the free thiol in glutathione-reduced BSA, and the other is to serve as a solvent for the active substance containing dihydromyricetin. If the amount of DMSO is too small, on the one hand BSA cannot be oxidized efficiently to form a gel, and on the other hand, a sufficient amount of active substance containing dihydromyricetin cannot be dissolved sufficiently because the solubility of dihydromyricetin in DMSO is 80 to 100mg/mL at the oxidation reaction temperature. However, too much DMSO will result in a gel that is somewhat cytotoxic. The dihydromyricetin serving as a sterilization component of the gel material is dissolved in DMSO and then is loaded to the BSA gel material, so that the concentration of the dihydromyricetin in the DMSO has certain requirements, the sterilization performance of the gel material is influenced by the too low concentration, and the dosage of the DMSO is increased due to the too high concentration, so that the gel has certain cytotoxicity.
The invention also provides an application of the in-situ dihydromyricetin-loaded BSA gel sterilization material in preparing a sterilization medicament.
The gel sterilization material has injectability, can be extracted through a needle tube, can be injected into a human body to realize different applications, has excellent sterilization effect, can slowly release dihydromyricetin, and has better inactivation effect on common bacteria such as escherichia coli, staphylococcus aureus and the like.
Compared with the prior art, the technical scheme of the invention has the advantages that:
(1) The BSA gel is used as a carrier material to load the dihydromyricetin, so that the solubility of the dihydromyricetin is improved, and the biocompatibility of the composite material is promoted;
(2) The dihydromyricetin is embedded in the gel, so that the dihydromyricetin can be slowly released, and the long-term and continuous sterilization effect is achieved;
(3) The gel is prepared by the reaction of DMSO and BSA for the first time, the DMSO is used as a weak oxidant and a broad-spectrum solvent at the same time, and dihydromyricetin can be loaded in situ and efficiently dispersed into the gel in the gel preparation process, so that the medicine loading in situ is realized and the medicine loading capacity is improved;
(4) The BSA-based gel sterilization material has the advantages of simple preparation method, mild condition and low cost, and is beneficial to large-scale production.
Drawings
Fig. 1 is a schematic diagram of the synthesis of the gel sterilization material of the present invention and a comparative diagram of the product synthesized under different conditions, wherein: (A) a synthetic schematic diagram of the gel sterilization material; (B) only BSA reacts with glutathione; (C) Adding DMSO (dimethyl sulfoxide) to prepare gel after BSA reacts with glutathione; (D) dissolving dihydromyricetin in DMSO.
FIG. 2 is a graph showing the slow release of dihydromyricetin by the gel sterilization material prepared in example 1.
Fig. 3 shows the sterilizing effect of the gel sterilization material and the control prepared in example 1 on escherichia coli and staphylococcus aureus, wherein the incubation of dihydromyricetin with bacterial solution, the incubation of pure bacterial solution, the incubation of DMSO with bacterial solution and the incubation of gel with bacterial solution are sequentially performed from left to right.
Fig. 4 shows the gel sterilization material prepared in example 1 injected through a syringe.
Detailed Description
The present invention will be described more fully hereinafter with reference to the accompanying drawings, in which preferred embodiments are shown, for the purpose of illustrating the invention, but the scope of the invention is not limited to the specific embodiments shown.
Unless defined otherwise, all technical and scientific terms used hereinafter have the same meaning as commonly understood by one of ordinary skill in the art. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the scope of the present invention.
Unless otherwise specifically indicated, the various raw materials, reagents, instruments, equipment and the like used in the present invention are commercially available or may be prepared by existing methods.
Example 1
An example of a gel sterilization material of the present invention is schematically shown in fig. 1. The specific preparation method of the gel sterilization material comprises the following steps:
(1) Glutathione (concentration of glutathione in the solution is 30 mM) was added to 5mL BSA solution (40 wt%) and the reduction reaction was carried out at 50℃for 5 hours;
(2) 1mL of the above solution was taken, and 50. Mu.L of DMSO solution containing 100mg/mL dihydromyricetin was added thereto to perform oxidation reaction at 50℃for 2 hours, thereby obtaining a gel antibacterial material.
The gel sterilization material prepared in example 1 was subjected to a dihydromyricetin release rate and release amount test, specifically, the gel and the buffer solution were incubated at room temperature, and the amount of dihydromyricetin released in the buffer solution was tested by ultraviolet spectrophotometry. As can be seen from FIG. 2, dihydromyricetin can be rapidly released from the gel within 12 hours, probably because the larger pores in the gel facilitate the release of dihydromyricetin. However, after 12 hours, the release speed of the dihydromyricetin is obviously slowed down, after 3 days, no dihydromyricetin is basically released, and after 5 days, the released dihydromyricetin reaches 65.91% of the loading capacity, which indicates that the gel sterilization material can realize the slow release of the dihydromyricetin, and the purpose of long-term stable sterilization is achieved.
Example 2
Another example of a gel sterilization material of the present invention is prepared by the following steps:
(1) Glutathione (concentration of glutathione in the solution was 50 mM) was added to 5mL of BSA (50 wt%) solution, and the reduction reaction was carried out at 40℃for 6 hours.
(2) 1mL of the above solution was taken, 50. Mu.L of DMSO solution containing 100mg/mL dihydromyricetin was added thereto, and oxidation reaction was carried out at 40℃for 3 hours to obtain a gel antibacterial material.
The gel sterilization material obtained by the preparation method of the embodiment shows obvious gel shape, and the gel performance is consistent with that of the gel material in the embodiment 1.
Example 3
The antibacterial performance of the gel antibacterial material prepared in example 1 was tested, specifically, the gel antibacterial material was incubated with a bacterial solution containing escherichia coli or staphylococcus aureus, and the antibacterial effect of the gel material was judged by observing the bacterial growth condition. Meanwhile, in order to better illustrate the sterilization performance of the gel material, three groups of control experiments are carried out, namely, pure bacteria incubation without any substances, dihydromyricetin incubation with bacteria liquid, DMSO incubation with bacteria liquid, and other operation conditions are kept unchanged.
As can be seen from FIG. 3, in the agar medium containing pure bacteria and DMSO, the E.coli and the Staphylococcus aureus grow vigorously, but in the agar medium containing the gel sterilization material or the dihydromyricetin, the E.coli and the Staphylococcus aureus do not obviously grow, which indicates that the gel sterilization material prepared by the method keeps the sterilization performance of the dihydromyricetin, shows excellent sterilization effect, and can be used as a sterilization material.
Example 4
An example of the application of the gel sterilization material of the present invention is that the gel has injectability, can be extracted through a needle tube, and can be injected into human bodies to realize different applications.
The above description is only of the preferred embodiments of the present invention and is not intended to limit the present invention, but various modifications and variations can be made to the present invention by those skilled in the art. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (8)
1. A BSA gel sterilization material loaded with dihydromyricetin in situ is characterized in that: the active substances containing dihydromyricetin are uniformly loaded in a BSA gel material;
the BSA gel material is obtained by sequentially reducing BSA by glutathione and oxidizing BSA by DMSO;
the content of dihydromyricetin in the BSA gel material is 3-5 mg/mL.
2. The in situ-supported dihydromyricetin BSA gel sterilization material according to claim 1, wherein the BSA gel sterilization material is characterized in that: the active substance containing dihydromyricetin is dihydromyricetin and/or vine tea extract containing dihydromyricetin.
3. The method for preparing the in-situ dihydromyricetin-loaded BSA gel sterilization material as claimed in claim 1 or 2, which is characterized by comprising the following steps: and (3) adding glutathione into the BSA solution to perform a reduction reaction, and then adding a DMSO solution containing active substances containing dihydromyricetin to perform an oxidation reaction to obtain the active substance.
4. The method for preparing the in-situ dihydromyricetin-loaded BSA gel sterilization material according to claim 3, wherein the method is characterized by comprising the following steps: the temperature of the reduction reaction is 40-50 ℃, and the reaction time is 3-6 h.
5. The method for preparing the in-situ dihydromyricetin-loaded BSA gel sterilization material according to claim 3, wherein the method is characterized by comprising the following steps: the temperature of the oxidation reaction is 40-50 ℃, and the reaction time is 1-3 h.
6. The method for preparing the in-situ dihydromyricetin-loaded BSA gel sterilization material according to claim 3, wherein the method is characterized by comprising the following steps:
the mass percentage concentration of the BSA solution is 30% -50%;
and the concentration of glutathione added into the BSA solution is 30-50 mM.
7. The method for preparing the in-situ dihydromyricetin-loaded BSA gel sterilization material according to claim 3, wherein the method is characterized by comprising the following steps:
the volume ratio of the DMSO solution to the BSA solution is 1:15-25;
the concentration of dihydromyricetin in the DMSO solution is 80-100 mg/mL.
8. Use of a BSA gel bactericidal material loaded with dihydromyricetin in situ as claimed in claim 1 or 2 for the preparation of a bactericidal medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210425222.2A CN114712305B (en) | 2022-04-22 | 2022-04-22 | In-situ dihydromyricetin-loaded BSA gel sterilization material, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210425222.2A CN114712305B (en) | 2022-04-22 | 2022-04-22 | In-situ dihydromyricetin-loaded BSA gel sterilization material, and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114712305A CN114712305A (en) | 2022-07-08 |
| CN114712305B true CN114712305B (en) | 2023-10-24 |
Family
ID=82246017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210425222.2A Active CN114712305B (en) | 2022-04-22 | 2022-04-22 | In-situ dihydromyricetin-loaded BSA gel sterilization material, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114712305B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102565161A (en) * | 2011-12-31 | 2012-07-11 | 中国人民解放军军事医学科学院卫生学环境医学研究所 | Two-dimensional molecular engram array type quality sensing detection method for staphylococcus enterotoxin |
| CN108514546A (en) * | 2018-05-14 | 2018-09-11 | 山东师范大学 | A kind of the aquagel preparation and preparation method of dihydromyricetin |
| CN110201191A (en) * | 2019-07-10 | 2019-09-06 | 莎穆(上海)生物科技有限公司 | A kind of functional protein and the compound of cyanine dye molecule and its preparation method and application |
| CN110305337A (en) * | 2018-03-27 | 2019-10-08 | 天津大学 | Untwist albumin hydrogel and preparation method thereof |
| CN112715939A (en) * | 2020-12-30 | 2021-04-30 | 杭州娃哈哈科技有限公司 | Preparation method of dihydromyricetin compound solution capable of being stably stored for long time |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2868308A1 (en) * | 2013-10-30 | 2015-05-06 | Lipotec, S.A. | Expolysaccharide for the treatment and/or care of skin, culture media and compositions thereof |
-
2022
- 2022-04-22 CN CN202210425222.2A patent/CN114712305B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102565161A (en) * | 2011-12-31 | 2012-07-11 | 中国人民解放军军事医学科学院卫生学环境医学研究所 | Two-dimensional molecular engram array type quality sensing detection method for staphylococcus enterotoxin |
| CN110305337A (en) * | 2018-03-27 | 2019-10-08 | 天津大学 | Untwist albumin hydrogel and preparation method thereof |
| CN108514546A (en) * | 2018-05-14 | 2018-09-11 | 山东师范大学 | A kind of the aquagel preparation and preparation method of dihydromyricetin |
| CN110201191A (en) * | 2019-07-10 | 2019-09-06 | 莎穆(上海)生物科技有限公司 | A kind of functional protein and the compound of cyanine dye molecule and its preparation method and application |
| CN112715939A (en) * | 2020-12-30 | 2021-04-30 | 杭州娃哈哈科技有限公司 | Preparation method of dihydromyricetin compound solution capable of being stably stored for long time |
Non-Patent Citations (4)
| Title |
|---|
| Injectable redox albumin-based hydrogel with in-situ loaded dihydromyricetin;Lei Deng等;Colloids and Surfaces B: Biointerfaces;全文 * |
| Study on the interaction between dihydromyricetin and bovine serum albumin by spectroscopic techniques;Xianyong Yu等;Journal of Molecular Structure;407-412 * |
| 二氢杨梅素抗肿瘤活性及作用机制研究进展;张婧;罗晓平;于之伦;岳备;任君宇;王浩;窦薇;;中国新药与临床杂志(第08期);全文 * |
| 荧光猝灭法研究二氢槲皮素和二氢杨梅素与牛血清白蛋白的相互作用;樊超;钟艺青;粟芸;李会娟;吴方评;金苹;;安徽医药(第11期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114712305A (en) | 2022-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107778497A (en) | A kind of compound covalently hydrogel and its preparation method and application discharged on demand | |
| CN112294752B (en) | AgNPs @ CSSCS nanogel drug-loading system and preparation thereof | |
| EP2510944A1 (en) | Treatment of bacterial infections | |
| CN112451738B (en) | Silver ion polysaccharide polymer antibacterial dressing and preparation method and application thereof | |
| JP2013505904A (en) | External disinfecting ointment comprising bentonite with silver, copper or zinc inserted | |
| EP3193614A1 (en) | Iodophor composition with improved stability in the presence of organic material | |
| CA2728456A1 (en) | Acetic acid and a buffer | |
| CN114712305B (en) | In-situ dihydromyricetin-loaded BSA gel sterilization material, and preparation method and application thereof | |
| CN111410754B (en) | S-nitrosothiol/polysaccharide-based in-situ forming hydrogel and preparation method and application thereof | |
| CN111991417A (en) | Hypochlorous acid gel with physiological responsiveness and application thereof in skin wound surface | |
| Han et al. | Biomimetic hydroxyapatite-chitosan nanoparticles deliver the erythromycin for improved antibacterial activity | |
| EP2170081B1 (en) | Antimicrobial compositions | |
| CN1850113A (en) | Amoxicillin antibacterial agent containing nano silver, and its preparing method and use | |
| CN102293689B (en) | Nano-silver testicular prosthesis | |
| CN104686578A (en) | Composite antibacterial powder | |
| CN108938559B (en) | DNA gel sterilization material, preparation method thereof and application of DNA gel sterilization material as sterilization material | |
| WO1999053754A1 (en) | Subversion of bacterial resistance by low solubility antibiotics | |
| CN114748450B (en) | Near-infrared response Bi/BiOCl heterojunction composite fibrin gel and preparation and application thereof | |
| US20240115773A1 (en) | Fibrinogen as adjuvant for antimicrobial agents and therapy | |
| CN106668062A (en) | Medicinal composition, application of medicinal composition to preparation of medicament for wound healing, medical preparation and medical bandage | |
| CN106673989A (en) | Pharmaceutical composition as well as preparation method and application thereof | |
| KR20230060724A (en) | Biocomposite and a method for producing thereof | |
| RU2151599C1 (en) | Antiseptic preparation | |
| CN117159780A (en) | Compound hemostatic and preparation method thereof | |
| CN117462738A (en) | Preparation method and application of sodium bicarbonate and hyaluronic acid mixed dressing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |